CD86 and prostate adenocarcinoma: In PRAD, LCN2 expression was positively correlated with expression of CD244, CD48, LGALS9, TNFSF14, TMIGD2, VTCN1, TNFSF9, TNFRSF8, CD27, TNFRSF25, VSIR, TNFRSF4, CD40, TNFRSF15, CD86, and CD44 (Figure 5A).